A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials | Zendy

Khalid AbdElaziz | Zendy; Ingrid Duijkers | Zendy; Lars Stöckl | Zendy; Bruno Dietrich | Zendy; Christine Klipping | Zendy; Kelvin Eckert | Zendy; Steffen Goletz | Zendy

Open Access

A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials

Author(s) -

Khalid AbdElaziz,

Ingrid Duijkers,

Lars Stöckl,

Bruno Dietrich,

Christine Klipping,

Kelvin Eckert,

Steffen Goletz

Publication year - 2017

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dex220

Subject(s) - placebo , pharmacokinetics , chinese hamster ovary cell , pharmacodynamics , medicine , recombinant dna , follicle stimulating hormone , endocrinology , pharmacology , hormone , biology , luteinizing hormone , receptor , pathology , biochemistry , alternative medicine , gene

What are the differences and similarities of pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the novel recombinant human FSH follitropin epsilon expressed in the human cell line GlycoExpress compared with a Chinese hamster ovary (CHO) derived compound and a urinary derived product?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research